Relationship between Insulin Resistance and Inflamation Markers in Hemodialysis Patients

REFERENCES

• Murphy SW, Foley RN, Parfey PJ. National Kidney Foundation Task Force on Cardiovascular Disease: Screening and treatment for cardiovascular disease in patients with cronic renal disease. Am J Kidney Dis. 1998;32:184–199.
   Google Scholar
• Ross R. Atherosclerosis—an inflammatory disease. N Eng J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–481.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473–486.
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Lamendola C, Differatiation between obesity and obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908–2912.
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrom and C-reactive protein, fibrinogen, and leukocyte count: Finding from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003;168:351–358.
   PubMed Web of Science ®Google Scholar
• Chen J, Wildman RP, Hamm LL, Association between inflammation and insulin resistance in U.S. nondiabetic adults. Diabetes Care. 2004;27:2960–2965.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and ß-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Horm Res. 2001;56:265–294.
   Google Scholar
• Matthaei S, Stumvoll M, Kellerer M, Haring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 2000;21:585–618.
   PubMed Web of Science ®Google Scholar
• Bergman RN, Ider ZY, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;26:667–677.
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Alberiche M, Homeostasis model assesment closy mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
   PubMed Web of Science ®Google Scholar
• Garber AJ. The metobolic syndrome. Med Clin North Am. 2004;88:837–846.
   PubMed Web of Science ®Google Scholar
• Meigs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep. 2003;3:737–739.
   Google Scholar
• Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47.
   PubMed Web of Science ®Google Scholar
• Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 2001;54 (Suppl. 2):S29–S33.
   Google Scholar
• Marchesini G, Brizi M, Bianchi G, Nonalcoholic fatty liver disease: A future of the metabolic syndrome. Diabetes. 2001;50:1844–1850.
   PubMed Web of Science ®Google Scholar
• Blake GJ, Ridker PM. Oval clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–771.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 1999;100:230–235.
   PubMedGoogle Scholar
• European Society of Hypertension—European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An eight-year follow-up of 14,719 initially healty American women. Circulation. 2003;107:391–397.
   PubMed Web of Science ®Google Scholar
• Swales J, de Bono D. Cardiovascular risk factors. Gower Medical Publishing, London, New York, 1993.
   Google Scholar
• Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25–29.
   PubMed Web of Science ®Google Scholar
• Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol. 1998;138:63–69.
   PubMed Web of Science ®Google Scholar
• Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008–3011.
   PubMed Web of Science ®Google Scholar
• Bo M, Raspo S, Morra F, Body fat is the main predictor of fibrinogen levels in healthy non-obese men. Metabolism. 2004;53:984–988.
   PubMedGoogle Scholar
• de Maat MP, Pietersma A, Kofflard M, Association of plasma fibrinogen levels with coronary heart disease, smoking and inflammatory markers. Atherosclerosis. 1996;121:185–191.
   PubMed Web of Science ®Google Scholar
• Moller L, Kristensen TS. Plasma fibrinogen and ischemic heart disease risk factors. Arteroscler Thromb. 1991;11:344–350.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;101:836–843.
   Google Scholar
• Chen J, Wildman RP, Hamm LL, Association between inflammation and insulin resistance in U.S. nondiabetic adults: Results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27:2960–2965.
   PubMed Web of Science ®Google Scholar
• Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057.
   PubMed Web of Science ®Google Scholar
• Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies. J Cardiovasc Risk. 1998;5:229–232.
   PubMedGoogle Scholar
• Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies. J Cardiovasc Risk. 1998;5:229–232.
   PubMedGoogle Scholar
• Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risk of cardiovascular disease: Causal or causal? Arch Intern Med. 2000;160:422–434.
   PubMed Web of Science ®Google Scholar